|
1
|
Khuhaprema T and Srivatanakul P: Colon and
rectum cancer in Thailand: an overview. Jpn J Clin Oncol.
38:237–243. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Moertel CG, Fleming TR, Macdonald JS, et
al: Fluorouracil plus levamisole as effective adjuvant therapy
after resection of stage III colon carcinoma: a final report. Ann
Intern Med. 122:321–326. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Sargent D, Sobrero A, Grothey A, et al:
Evidence for cure by adjuvant therapy in colon cancer: observations
based on individual patient data from 20,898 patients on 18
randomized trials. J Clin Oncol. 27:872–877. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Chau I and Cunningham D: Adjuvant therapy
in colon cancer - what, when and how? Ann Oncol. 17:1347–1359.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Chung-Faye GA and Kerr DJ: ABC of
colorectal cancer: innovative treatment for colon cancer. BMJ.
321:1397–1399. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Powis G and Montfort WR: Properties and
biological activities of thioredoxins. Annu Rev Biophys Biomol
Struct. 30:421–455. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Lim JY, Yoon SO, Hong SW, Kim JW, Choi SH
and Cho JY: Thioredoxin and thioredoxin-interacting protein as
prognostic markers for gastric cancer recurrence. World J
Gastroenterol. 18:5581–5588. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Powis G and Montfort WR: Properties and
biological activities of thioredoxins. Annu Rev Pharmacol Toxicol.
41:261–295. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Nakamura H, Bai J, Nishinaka Y, et al:
Expression of thioredoxin and glutaredoxin, redox-regulating
proteins, in pancreatic cancer. Cancer Detect Prev. 24:53–60.
2000.PubMed/NCBI
|
|
10
|
Raffel J, Bhattacharyya AK, Gallegos A, et
al: Increased expression of thioredoxin-1 in human colorectal
cancer is associated with decreased patient survival. J Lab Clin
Med. 142:46–51. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Ueno M, Masutani H, Arai RJ, et al:
Thioredoxin-dependent redox regulation of p53-mediated p21
activation. J Biol Chem. 274:35809–35815. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Welsh SJ, Bellamy WT, Briehl MM and Powis
G: The redox protein thioredoxin-1 (Trx-1) increases
hypoxia-inducible factor 1α protein expression: Trx-1
overexpression results in increased vascular endothelial growth
factor production and enhanced tumor angiogenesis. Cancer Res.
62:5089–5095. 2002.PubMed/NCBI
|
|
13
|
Abate C, Patel L, Rauscher FJ III and
Curran T: Redox regulation of fos and jun DNA-binding activity in
vitro. Science. 249:1157–1161. 1990. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Kakolyris S, Giatromanolaki A, Koukourakis
M, et al: Thioredoxin expression is associated with lymph node
status and prognosis in early operable non-small cell lung cancer.
Clin Cancer Res. 7:3087–3091. 2001.PubMed/NCBI
|
|
15
|
Grogan TM, Fenoglio-Prieser C, Zeheb R, et
al: Thioredoxin, a putative oncogene product, is overexpressed in
gastric carcinoma and associated with increased proliferation and
increased cell survival. Hum Pathol. 31:475–481. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Jordan BF, Runquist M, Raghunand N, et al:
The thioredoxin-1 inhibitor 1-methylpropyl 2-imidazolyl disulfide
(PX-12) decreases vascular permeability in tumor xenografts
monitored by dynamic contrast enhanced magnetic resonance imaging.
Clin Cancer Res. 11:529–536. 2005.PubMed/NCBI
|
|
17
|
Gallegos A, Gasdaska JR, Taylor CW, et al:
Transfection with human thioredoxin increases cell proliferation
and a dominant-negative mutant thioredoxin reverses the transformed
phenotype of human breast cancer cells. Cancer Res. 56:5765–5770.
1996.PubMed/NCBI
|
|
18
|
Wipf P, Hopkins TD, Jung JK, et al: New
inhibitors of the thioredoxin-thioredoxin reductase system based on
a naphthoquinone spiroketal natural product lead. Bioorg Med Chem
Lett. 11:2637–2641. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Kirkpatrick DL, Kuperus M, Dowdeswell M,
et al: Mechanisms of inhibition of the thioredoxin growth factor
system by antitumor 2-imidazolyl disulfides. Biochem Pharmacol.
55:987–994. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Ramanathan RK, Kirkpatrick DL, Belani CP,
et al: A phase I pharmacokinetic and pharmacodynamic study of
PX-12, a novel inhibitor of thioredoxin-1, in patients with
advanced solid tumors. Clin Cancer Res. 13:2109–2114. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Uchiyama S, Itoh H, Naganuma S, et al:
Enhanced expression of hepatocyte growth factor activator inhibitor
type 2-related small peptide at the invasive front of colon
cancers. Gut. 56:215–226. 2007. View Article : Google Scholar
|
|
22
|
Yamazaki K, Shimizu M, Okuno M, et al:
Synergistic effects of RXRα and PPARγ ligands to inhibit growth in
human colon cancer cells - phosphorylated RXRα is a critical target
for colon cancer management. Gut. 56:1557–1563. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Shen D, Deng C and Zhang M: Peroxisome
proliferator-activated receptor γ agonists inhibit the
proliferation and invasion of human colon cancer cells. Postgrad
Med J. 83:414–419. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Noike T, Miwa S, Soeda J, Kobayashi A and
Miyagawa S: Increased expression of thioredoxin-1, vascular
endothelial growth factor, and redox factor-1 is associated with
poor prognosis in patients with liver metastasis from colorectal
cancer. Hum Pathol. 39:201–208. 2008. View Article : Google Scholar
|
|
25
|
Lillig CH and Holmgren A: Thioredoxin and
related molecules - from biology to health and disease. Antioxid
Redox Signal. 9:25–47. 2007. View Article : Google Scholar
|
|
26
|
Arnér ES: Focus on mammalian thioredoxin
reductases - important selenoproteins with versatile functions.
Biochim Biophys Acta. 1790:495–526. 2009. View Article : Google Scholar
|
|
27
|
Vogt A, Tamura K, Watson S and Lazo JS:
Antitumor imidazolyl disulfide IV-2 causes irreversible
G2/M cell cycle arrest without hyperphosphorylation of
cyclin-dependent kinase Cdk1. J Pharmacol Exp Ther. 294:1070–1075.
2000.PubMed/NCBI
|
|
28
|
Shin HR, You BR and Park WH: PX-12-induced
HeLa cell death is associated with oxidative stress and GSH
depletion. Oncol Lett. 6:1804–1810. 2013.PubMed/NCBI
|
|
29
|
Krause KH: Tissue distribution and
putative physiological function of NOX family NADPH oxidases. Jpn J
Infect Dis. 57:S28–S29. 2004.PubMed/NCBI
|
|
30
|
Juhasz A, Ge Y, Markel S, et al:
Expression of NADPH oxidase homologues and accessory genes in human
cancer cell lines, tumours and adjacent normal tissues. Free Radic
Res. 43:523–532. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Bartolomé RA, Barderas R, Torres S, et al:
Cadherin-17 interacts with α2β1 integrin to regulate cell
proliferation and adhesion in colorectal cancer cells causing liver
metastasis. Oncogene. 33:1658–1669. 2014. View Article : Google Scholar
|
|
32
|
Gumireddy K, Li A, Gimotty PA, et al:
KLF17 is a negative regulator of epithelial-mesenchymal transition
and metastasis in breast cancer. Nat Cell Biol. 11:1297–1304. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Fuentes MK, Nigavekar SS, Arumugam T, et
al: RAGE activation by S100P in colon cancer stimulates growth,
migration, and cell signaling pathways. Dis Colon Rectum.
50:1230–1240. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Logsdon CD, Simeone DM, Binkley C, et al:
Molecular profiling of pancreatic adenocarcinoma and chronic
pancreatitis identifies multiple genes differentially regulated in
pancreatic cancer. Cancer Res. 63:2649–2657. 2003.PubMed/NCBI
|
|
35
|
Guerreiro Da Silva ID, Hu YF, Russo IH, et
al: S100P calcium-binding protein overexpression is associated with
immortalization of human breast epithelial cells in vitro and early
stages of breast cancer development in vivo. Int J Oncol.
16:231–240. 2000.PubMed/NCBI
|
|
36
|
Diederichs S, Bulk E, Steffen B, et al:
S100 family members and trypsinogens are predictors of distant
metastasis and survival in early-stage non-small cell lung cancer.
Cancer Res. 64:5564–5569. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Mishra SK, Siddique HR and Saleem M:
S100A4 calcium-binding protein is key player in tumor progression
and metastasis: preclinical and clinical evidence. Cancer
Metastasis Rev. 31:163–172. 2012. View Article : Google Scholar
|
|
38
|
Boye K and Maelandsmo GM: SS100A4 and
metastasis: a small actor playing many roles. Am J Pathol.
176:528–535. 2010. View Article : Google Scholar :
|
|
39
|
Huang LY, Xu Y, Cai GX, et al: S100A4
over-expression underlies lymph node metastasis and poor prognosis
in colorectal cancer. World J Gastroenterol. 17:69–78. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Stein U, Arlt F, Walther W, et al: The
metastasis-associated gene S100A4 is a novel target of
β-catenin/T-cell factor signaling in colon cancer.
Gastroenterology. 131:1486–1500. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Orre LM, Panizza E, Kaminskyy VO, et al:
S100A4 interacts with p53 in the nucleus and promotes p53
degradation. Oncogene. 32:5531–5540. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Sack U, Walther W, Scudiero D, et al:
S100A4-induced cell motility and metastasis is restricted by the
Wnt/β-catenin pathway inhibitor calcimycin in colon cancer cells.
Mol Biol Cell. 22:3344–3354. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Jiang L, Lai YK, Zhang J, et al: Targeting
S100P inhibits colon cancer growth and metastasis by
lentivirus-mediated RNA interference and proteomic analysis. Mol
Med. 17:709–716. 2011. View Article : Google Scholar : PubMed/NCBI
|
